Adipotide is a peptide designed for treating obesity by targeting white adipose tissue through a dual-domain mechanism that induces endothelial cell apoptosis. Preclinical studies indicate its effectiveness in weight reduction and metabolic improvement, although dose-dependent nephrotoxicity raises safety concerns. Formulation strategies are being explored to enhance its therapeutic potential while minimizing off-target effects.
subcutaneous, intravenous
0.5-2.5 mg/kg
2-4 hours
Stable when lyophilized, requires cold storage
Prohibitin, White adipose tissue vasculature
Adipotide was developed as a targeted therapeutic approach for obesity treatment, representing a paradigm shift from traditional metabolic interventions to direct adipose tissue destruction . The compound was designed based on the principle of vascular targeting, specifically focusing on the unique vascular signature of white adipose tissue .
Prohibitin
White adipose tissue vasculature
Research Use Only (RUO) - Adipotide: A Novel Peptide for Obesity Treatment is currently available for research purposes only and is not approved by regulatory agencies for human therapeutic use.
This report is generated for educational and informational purposes only. All research content is compiled from credible, peer-reviewed, and verified external scientific sources. This material does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any decisions related to your health or treatment.
Explore the clinical applications and protocols of Adipotide-FTPP, a promising peptide in obesity treatment. Discover its mechanisms, benefits, and practical guidelines for use.
April 25, 2026
Explore how Adipotide-FTPP targets fat cells through apoptosis, leading to weight reduction. Understand the science behind this peptide's mechanism of action and its potential applications in obesity management.
April 19, 2026